BioSpace News Archive

Century Therapeutics announced the presentation of initial clinical data from a single-patient case study which Century believes support the potential for a multi-dosing strategy for CAR iNK enabled by Allo-Evasion™ edits at the 65th American Society of Hematology Annual Meeting and Exposition, being held December 9-12 in San Diego.

Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882.

The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that remove germs.

FibroGen, Inc. announced the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes at the 65th American Society of Hematology Annual Meeting and Exposition being held in San Diego, California December 9 - 12, 2023.

Orca Bio announced positive new data that suggest its investigational high-precision cell therapies, Orca-T and Orca-Q, have the potential to deliver improved clinical outcomes across different age ranges, donor types and conditioning regimens relative to existing standard of care allogeneic hematopoietic stem cell transplants.

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia at the 65th American Society of Hematology Annual Meeting and Exposition.

Agios Pharmaceuticals, Inc. presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell disease in an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition, which is being hosted Dec. 9-12, 2023, in San Diego.